Top 10 Penny Stocks That Will Skyrocket

Page 9 of 9

1. Iovance Biotherapeutics, Inc. (NASDAQ:IOVA)

Price: $3.54

Analyst Upside Potential: 464.97%

Number of Hedge Fund Holders: 44

Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) is a biopharmaceutical company focused on developing and delivering tumor-infiltrating lymphocyte (TIL) therapies for the treatment of solid tumor cancers. Its Amtagvi is the first FDA-approved TIL therapy for advanced melanoma. It is an autologous T-cell immunotherapy used for patients with unresectable or metastatic melanoma who have been previously treated with specific therapies such as PD-1 inhibitors.

On March 1, Analyst Joseph Pantginis of H.C. Wainwright reiterated a Buy rating on the stock with a price target of $32. The analyst noted that Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) exceeded revenue expectations for Q4 and the full year of 2024, driven by robust demand for its products, Amtagvi and Proleukin. The company also maintained its revenue guidance of $450 million to $475 million for 2025, reflecting confidence in sustained growth. Moreover, progress in tumor-infiltrating lymphocyte therapies, particularly in addressing unmet medical needs like endometrial cancer, was highlighted. Upcoming data releases and advancements in next-generation TIL therapies further support the company’s potential. It is the top penny stock that will skyrocket.

While we acknowledge the potential of Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) to grow, our conviction lies in the belief that AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than IOVA but that trades at less than 5 times its earnings, check out our report about the cheapest AI stock.

READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires.

Disclosure. None. Insider Monkey focuses on uncovering the best investment ideas of hedge funds and investors. Please subscribe to our daily free newsletter to get the latest investment ideas from hedge funds’ investor letters by entering your email address below.

Page 9 of 9